FDA Greenlights First Human Kratom Trial Amid Diverging Policy on 7-OH

Why it matters

The FDA's approval of a clinical trial for purified mitragynine may signal a shift in federal kratom policy, distinguishing natural kratom alkaloids from synthetic 7-OH derivatives. This development has major implications for ongoing state-level bans, DEA scheduling decisions, and the future legal status of kratom products.

The big picture

The U.S. has been navigating contradictory signals on kratom regulation: in July 2025, the FDA recommended scheduling 7-OH as a Schedule I controlled substance, while simultaneously not targeting natural kratom. Now, ten months later, the DEA has not acted on the 7-OH recommendation, and the FDA has cleared the first human trial of a kratom compound. This creates a complex regulatory landscape where the same plant's derivatives could face opposite regulatory fates.

Key findings

• The FDA approved an IND for MG001 (purified mitragynine) — the first-ever randomized, double-blind, placebo-controlled human trial of a kratom compound
• The study will enroll approximately 32 healthy volunteers and is funded under the NIH HEAL Initiative
• The FDA's July 2025 recommendation to classify 7-OH as Schedule I has not yet been acted upon by the DEA, ten months later
• President Trump referenced his administration's interest in "natural 7-OH" at a May 2026 Oval Office event, signaling possible policy support
• The regulatory divergence between natural kratom and synthetic 7-OH is becoming more pronounced at both federal and state levels

What they say

"This research study is the first time the new medication MG001 is being tested in people. The purpose of this study is to understand how safe MG001 is, how well it is tolerated, and how the body processes it," states a National Institute on Drug Abuse clinical trial summary.

Bottom line

The FDA clearing NIH's first human trial of a kratom compound — while the DEA delays action on 7-OH scheduling — signals a U.S. regulatory approach that may preserve natural kratom as a therapeutic candidate while targeting synthetic derivatives.